AbbVie Inc. Buyback
OLI recorded this information on 12/13/2018
Company:
AbbVie Inc.
Buyback:
ABBV buyback
$Amount Authorized:
$5,000,000,000
Buyback Details:
The board of directors of AbbVie Inc. (NYSE: ABBV) has authorized a $5 billion increase to AbbVie's existing stock repurchase program.
AbbVie is a research-based biopharmaceutical company. Co. operates as a single business segment dedicated to the research and development, manufacturing, commercialization and sale of medicines and therapies. Co.'s products include: immunology products such as Humira, Skyrizi, and Rinvoq; oncology products such as Imbruvica and Venclexta/Venclyxto; aesthetics products such as Botox Cosmetic and Juvederm Collection; neuroscience products such as Botox Therapeutic, Vraylar, and Ubrelvy; eyecare products such as Lumigan/Ganfort, Alphagan/Combigan, and Restasis; women's health products such as Lo Loestrin and Orilissa/Oriahnn; and other key products such as Creon, Lupron, and Synthroid.
AbbVie SEC Filing Email Alerts Service
Open the ABBV Page at The Online Investor »
|
||||||||||||||||||||||||
Open the ABBV Page at The Online Investor (in a new window) »
 Free ABBV Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
 
|
Buy (3.03 out of 4) 22nd percentile
(ranked lower than approx. 78% of all stocks covered)
Analysts' Target Price: ABBV Stock Forecast Based on Zacks ABR data; powered by Xignite |
